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event free survival was 54%. In conclusion, UCBT is an alterna- 
tive source of hematopoietic stem cells for the treatment of chil- 
dren with malignant and non-malignant diseases who lack a suit- 
able related onor. 
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A-LOCUS MISMATCH DOES NOT ADVERSELY INFLUENCE OUTCOME 
FOLLOWING RELATED-DONOR STEM CELL TRANSPLANTATION (SCT) 
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For pts with hematologic diseases requiring SCT who lack a his- 
tocompatible sibling, alternative related-donors (ARD) may be 
considered. Recent evidence suggests that outcome may also 
depend upon the parental source of the mismatched (M/M) haplo- 
type. We reviewed data on 42 pts that underwent ARD-SCT at 
VGH between 01/83 and 05/02:24 males and 18 females with a 
median age of 36 years. Diagnoses included AML (13 pts), CML 
(11 pts), ALL (8 pts) and other (10 pts). Fourteen pts had good 
risk disease. HLA testing was serologic until DNA techniques 
were instituted for class I (02/01) and class II (03/93) typing. 
Donor/recipient were phenotypic matches (PM)(3 pts), one-anti- 
gen M/M (36 pts; A-locus 19 pts, B-locus 6 pts, DR-locus 11 pts) 
or two-antigen M/M. Donors included a sibling (31 pts), a parent 
(8 pts), a child (1 pt) or a first cousin (2 pts). Stem cell source was 
bone marrow in 38 pts, blood in 3 pts or both in 1 pt. Forty pts 
initially engrafted; the remaining 2 pts were rescued with autolo- 
gous (1 pt) or allogeneic (1 pt) blood cells. One pt experienced late 
graft failure requiring a second SCT from the original donor. 
Nine pts died of acute/chronic GVHD, 2 pts from infection and 5 
frmn other causes. Seven pts died of recurrent disease. Nineteen 
pts (45%) remain alive (17 pts in CR, 2 pts in relapse) with a 
median followup of 8.8 (0.3-13.i) years. Pts having had a BMT 
from a one-antigen A-M/M or PM donor (Group 1, n=22) have a 
5 year overall smwival (OAS) of 63 %, treatment related mortality 
(TRM) of 25% and relapse rate (RR) of 16%. For all other pts 
(Group 2) OAS is 19% (p=0.01), TRM is 71% (p=0.01) and RR is 
45% (p=0.05). Incidence of acute GVHD for Group 1 and Group 
2 pts was similar[73% and 65%, respectively (p=0.4)]. There were 
more good-risk pts in Group 1 than in Group 2 (48% vs 20%, 
p=0.10). Five pts received SCT from sibling donors mismatched 
for noninherited maternal antigens (N1MA), 2 of whom are alive 
at 9.8 and 8 years respectively. Two pts received SCT from a sib- 
l ing donor mismatched for noninher i ted paternal antigens 
(NIPA), both of whom have died. ARD-SCT pts that are PM or 
one-antigen A-locu M/M with their donor appear to have out- 
comes similar to that reported for histocompatible siblings. Due 
to low pt nmnbers, the influence of parental donation and the use 
of a sibling with NIMA (rather than N[PA) couldl not be deter- 
mined. 
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THE ABSENCE OF MHC CLASS I ON NEURAL STEM CELLS DOES NOT 
PERMIT NK KILLING AND PREVENTS RECOGNITION BY ALLOREAC- 
TIVE CTL 
l~Iammolenti, 3/I.1; Gajavelli, S.2; Tsozdflts, p.2; Lezg~, R.B.t i. Uniw'r 
sity of 3liami - Microbiology and lnnnu,ology, Miami, FL; 2. Univer- 
sity of Miami - Neurosw'ge'u, Miami, FL. 
Potential applications of neural stem cells (NSC) in syngeneic 
and allogeneic progenitor cell transplantation models requires 
understanding of expression of MHC nmlccules and the ability of 
T cells and NK cells to recognize this progenitor population. 
Cells from the cortices of day 13 embryonic (El3) B6 (I I-2 b) mice 
were explanted and culture(] in serum free N2 media with basic 
fibroblast growth fiactor to select for NSC. Flow cytometric analy- 
sis of cells from P2 through P17 cultures using anti-MHC class 1 
and II mAb showed marginal evels of MI IC H-2K and H-2D 
class I and H-2IA class II expression. However, t itration of 
mr lFN 7 in NSC cultures demonstrated that MHC molecules 
could be strongly upregulated following addition of 3 ng/ml 
mrIFN 7 for 60 hours. To assess the susceptibility of NSC with 
marginal versus high levels of MHC expression to lysis by CTL 
and NK populations, 4 hour 51Cr release assays employing 
untreated and mrlFN 7 treated NSC target cells were performed. 
Results showed that untreated NSC were not recognized by 
BALB/c (H-2 d) allospecific anti-H-2 b CTL, consistent with the 
anti-MHC class I mAb findings. However, upregulation of class I
and II products on both early and later passaged NSC resulted in 
their efficient lysis by CTL. NK  cells were prepared from syn- 
geneic B6 or allogeneic BALB/c mice. Although NK cells effec- 
tively ~lled control YAC-1 target cells, they did not ~11 MHC 
deficient (or expressing) NSC targets. IL 2 augmented NK effec- 
tor ceils also failed to lyse NSC target cells. The findings suggest 
that following transplant of NSC into syngeneic recipients, these 
progenitor cells may not be susceptible to clearance by host NK 
ceils. Their lack of MHC expression may also help to shield such 
cells from immediate host allogeneic T cell recognition. 
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HAPLOIDENTICAL CD34 POSITIVE CELL TRANSPLANTATION IN 
PATIENTS WITH HEMATOLOGICAL MALIGNANCIES 
Tanigztchi, SJ; Ohno, j~ l; J~lineishi, S.:; Kamimzrra, Td; Eamasa- 
ki, S. s; Gondo, Hd; Takaz~e, }22; Harada, M. 1 1. Fukztoka BMT 
Groztp, Fzlk~toka, Japan; 2. Natinal CaTzcer Center Hospital, 
Tok),o, yapa.. 
Much more stem cell sources for allogeneic hematopoietic stem 
ceil transplantation (HST) have been available in this decade such 
as unrelated onors from marrow bank and cord blood bank in 
addition to HLA identical siblings. However, in cases of the 
urgent settings, transplant from haplo-identical related donors is 
the only choice for HST. A multi-center retrospective study is 
conducted to evaluate the feasibility of haplo-identical CD34 pos- 
itive cell transplant from related donors with more than 2 HLA 
loci mismatch. Between 1996 and 2001, a total of 25 patients with 
a variety of hematological malignancy received HST from haplo- 
identical related donors after CD34 positive cell selection. Patient 
mean age was 29 years old ranging from 17 to 69. Two patients 
with ALL/CR1 and 1 MDS (RA) patient were classified as a low 
risk group and 22 as a high risk group with advanced stage which 
is above CRI including 9 cases of second transplantation. All 
patients received positively selected CD34 peripheral blood stem 
cells isolated by CliniMACS (n=15) or Isolex 50 (n=10) system. 
Nineteen patients were conditioned with a conventional TBI con- 
taining regimen and 6 with a reduced-intensity regimen (RIST). 
GVHD prophylaxis were as follows; cyclosporine-based in 18, 
tacrolimus-based in 7 and MMF was added in 3 cases. Primary 
engraftment failure was observed in 6 out of 25 patients. Out of 6 
cases in RIST group, 3 patients were rejected. Later rejection 
after engraftment in day 28 was seen in 1 out of 19 patients evalu 
able. Sepsis with bacterial infection was seen in 9 patients, 2 of 
whom died. Fungal infections occurred in 9 patients, 2 of whom 
died. Regimen-related toxicity (RRT) was also highly observed, 3
patients died of RRT. Three cases died of lethal GVHD and 5 
cases of tumor progression. Eight of 9 second transplant cases 
died within 120 days. The estimated probability of relapse free 
survival (RFS) at 1 year was 23.3 % in all patients, 33.3 % (n=3) 
in the low-risk group and 21.6% in the high risk group (n=22). 
Engraftment failure, infectious disease, RRT and tumor progres- 
sion were the major cause of death. These data indicate that the 
nmre immunosnppressive regimen for engraftment, infection and 
tumor control at transplant are important to obtain better esults. 
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(HSCT) FOR ACUTE AND CHRONIC LYMPHOID MALIGNANCIES: 20 YEAR 
EXPERIENCE OF THE LEUKEMIA/BMT PROGRAM OF BRITISH COLUMBIA 
%ze, C.; Nevill, T.; Nantel, S.; Fo~west, D.; Shepherd, ft.; Phillips, G.; 
SoJzg, IC; Sntherland, H.; Lavoie, J.; Hogge, D. Leztkemia/BMT Pro- 
gram of British Columbia (Be), DivMon of Hematology, Vancozlver 
Hospital and Health Sdences Cen,'e, BC Ca~zce'r Agem),, and the Uni- 
verdty of British Cbhmzbi,, Vancouver, BC, Canada. 
The role of alternative, unrelated (UD) or HLA mismatched 
related (nunrd) HSC donors for acute and chronic lymphoid 
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malignancy is less well defined than for the myeloid counterparts. 
Between Jan 83 and Sept 02, 86 such patients (pts) proceeded to 
allogeneic HSCT at the Leukemia/BMT Program of BC. Diag- 
noses (dx) included ALL in 37 (12 Ph+), NHL  in 27 (2 special- 
Burkitt's or lymphoblastic lymphoma; 14 aggressive or trans- 
formed; 11 indolent), CLL in 3, PLL in 1, and myeloma in 18 pts. 
Median (reed) age was 36 (range 12-53) yrs; 52 (60%) were male. 
Med interval dx to HSCT was 9.7 mos (range 1.6 mos to 14.7 yrs). 
Disease status was intermediate or advanced in the majority (7I 
pts, 83%). Donors were mmrd in 14 cases (1 Ag mm in 13, 2 Ag 
mm in 1 pt), and UD in 72 pts (1 Ag mm in 14 pts, 2 Ag mm in 1, 
the remainder HLA matched). Stem cell source was marrow in the 
majority (n=82, 95%); peripheral blood (pb) alone in 2 cases and 
pb + marrow in 2. Conditioning included TBI for most (79pts, 
92%). GVHD prophylaxis was CSP + MTX +/- other for 71 
(82%); T-cell depletion was employed in I2 cases (14%). Engraft- 
ment  (range) of ANC > 0.Sx109/L; WBC > I.OxlOp/L and 
platelets > 20xlO9/L; occurred a reed of 19 (9-33); 20 (9-32); and 
27 (6-124) days respectively. Graft failure occurred in 4 pts. Inci- 
dence of acute GVHD grades II-W; III-1V and chronic GVHD 
was 74%; 46%; and 76%. Thirty-three pts (38%) survive a reed of 
3.6 yrs (range 1 mo - 12 yrs) post HSCT. Fifty three pts (62%) 
are deceased, 19 with relapse (REL) a reed of 353 days and 34 
with non-relapse mortality (NRM) a med of 66 days post HSCT. 
For NRM deaths, GVHD contributed in 21 pts, infection in 7 
including 3 cases of EBV assoc LPD, and RRT in 6 (5 puhn, 1 
VOD) to the cause of death. Four patients have sustained avascu- 
lar necrosis of large joints. Cumulative incidence estimates of 
NRM; REL; EFS and OS are 42%; 31%; 28% and 31%. In con- 
clusion: 1. About 1/3 of pts with lymphoid malignancies receiving 
HSCT from alternative donors achieved long-term survival, with 
the lead pts out more than 10 years. 2. The incidence of relapse is 
reasonable but still significant in this cohort where 'graft vs malig- 
nancy' would be expected to be strongly operative. 3. GVHD and 
infection remain challenging problems in this setting. 
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COMBINATION SIROLIMUS AND TACROLIMUS IMMUNOPROPHYLAXIS 
PROMOTES ENGRAFTMENT OF HAPLOIDENTICAL AND ALTERNATIVE 
DONOR STEM CELLS WITH NON-MYELOABLATIVE CONDITIONING IN 
ELDERLY AND POOR PROGNOSIS PATIENTS 
Claxto~, D.F.; Popesclf, D.; Kopp, 31.; Ebmaml, C.; Rybka, ~ Medi- 
ci*~e/Hem-OJzc, PeJzJz State College of Med, He'J',~'hey 3h'dical Cezzte'v, 
Hershey, PA. 
Between 4/2001 and 8/2002 16 patients 44-72 years old (median 
63) received non-ablative stem cell transplantation with Sirolimus 
(Siro) + Tacrolimus (Tacro) immunoprophy]axis. Diagnoses were: 
AML - 8, NHL  - ~, ALL - 1, CML/Philadelphia negative - 1, and 
CLL-1. Patients had failed 1-5 chemotherapy regimens. All 
received Fludarabine 25rag/m2 d-7 to -3 and Cyclophosphamide 
1 gin/m2 d-7 and -6. Siro began d-7 and Tacro d-3. Both were 
targeted to 5-10ng/lnl. SCT was dO and MTX 5rag/m2 dl, 3 and 
6. Patients with 3/6 or 4/6 matched donors received ATG d-l, 1, 
3, and 5. Patient-donor matches were: 6 -5/6 HLA matched, 3 - 
4/6 matched, 2 3/6 matched, 4 matched unrelated donors - all 
peripheral SCT. One received 4/6 matched cord blood cells. Sur- 
vival at 100-days was 86.66% (i3/I5). Overall survival was 62.5% 
(10/16 Pts, median follow-up d184). The cord blood recipient 
died d26 without stable engraftment. 4 of 5 patients with 3/6 or 
4/6 matched onors died, d37 (cerebrovascular ccident), d32 and 
d158 (coinplications of GVHD). Two died of leukemia d170 and 
d119. All others remain alive including one with a 4/6-matched 
donor -d315. 11/12 (91.6%) alive at day 100 had >95% donor 
engrafunent. One 5/6 matched recipient had only transient donor 
chimerism but recovered with autologous cells. 15/16 patients 
achieved ANC >500/ul (d5-19, median dl0.) 14/16 patients 
achieved platelets >50, 000/ul (d10-60, median dis  - in 2 platelets 
were never <50, 000/uh) Most patients developed elevated creati- 
nine - Max 0.7 to 6.Smg/dl (median 2.95mg/dl). No dialysis was 
required, but creatinine >2.Smg/dl d40-150 prompted withdrawal 
of Tacro in 5 patients. Three had Tacro withdrawn per protocol 
because of risk of relapse. In only one has Tacro tapering clearly 
resulted in GVHD (grade 2, skin). Max cholesterol was 122-527 
mg/dl (median 295.5 mg/dI) and triglyccrides 123-1366mg/dl 
(median 427mg/dl). Drug levels had no correlation with renal or 
lipid toxicities or engraftment. GVHD was: none -4 pts, grade 2 
in 11, grade 3 in I by day 100. Tacro l imus and Sirol imus 
immunoprophylaxis yields relatively effective engraftment in eld- 
erly and poor prognosis patients receiving alternative and hap- 
loidentical donor stem cell transplautation. 
IMMUNE RECONSTITUTION 
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RECONSTITUTION OF NR CELL RECEPTOR REPERTOIRE FOLLOWING 
HLA-MATCHED HEMATOPOIETIC CELL TRANSPLANTATION 
M,'Qztee77, K.L.S; Shillillg, H.G. 1; Ctae1~g, N. ~K 1; Shiszcl'zl, a%4. ~-; 
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The interactions between killer immunoglobulin-like r ceptors 
(KIR) and their human leukocyte antigen (HLA) class I ligands 
are important for NK cell functions and evelopment of NK cell 
receptor repertoires. The fact that both KIR and HLA class I, 
encoded on separate chromosomes, are highly polymorphic pre- 
dicts that the majority of hematopoietic cell transplantations will 
be KIR-mismatched. Consequently, we have used allogeneic 
transplantation as a tool to examine development of NK cell 
receptor epertoires under conditions of KIR and/or I ILA differ- 
ence. Eighteen leukemia patients receiving transplants and their 
donors were analyzed for KIR genotype. Ten  of 13 HLA- 
matched sibling transplants were K/R mismatched while three 
were matched. All unrelated transplants were K/R-mismatched. 
Reconstitution of NK receptor epertoire was examined follow- 
ing t ransplantat ion by flow cytometry using KIR and 
CD94:NKG2A-speeif ic monoclonal antibodies. Three distinct 
patterns of reconstitution were observed. Eight patients reconsti- 
tuted NK cell repertoires like that of the donor and distinct from 
the recipient within the first year post-transplantation. I  con- 
trast, five patients exhibited a generally depressed frequency of 
KIR-expressing NK cells, while CD94:NKG2A expression 
remained high during the first year post transplantation. In three 
of these patients analyzed three years post-transplant, the fre- 
quency of KiR-expressing NK cells had increased to donor lev- 
els. The remaining five patients experienced severe clinical com- 
pl ications fol lowing transplantat ion and displayed unique 
patterns of reconstitution. These results demonstrate that KIR- 
mismatch occurs in the majority of H/~/-matched hematopoietic 
cell transplants and that most patients reconsitute donor-type 
KIR phenotypes. Prelimina W results fi'om a larger study to exam- 
ine the impact of K/R-mismatch on transplant outcome will be 
presented. 
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ENHANCED T-CELL NEOGENESIS FOLLOWING NON-MYELOABLATIVE 
ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA- 
TION (NM-HSCT) 
Hochl, eJ'g, E.P. 7; Levi~z, J.A. 1; ,41yea, E.P. 1; A~th~, ff.H. 1; Soiff~v, 
R.ff. 1; Rit~, 57.1 1. Medk'al O~zcolo©,, DaTza Favl, ev Calzc'er blstitz~te, 
Boston1, M/l; 2. BJ'igham alld T'VomeT~ ;" Hospital, Bostoll, MA. 
Measurements of T ceil reconstitution after adult allogencic 
hematopoietic stem cell transplant provide early biologic corre- 
lates for the clinical endpoints of fimctional inmmnity and disease 
free smwivah Quantitative PCR for T cell receptor excision circles 
(TREC) is an accurate measurement of the generation of new T 
cells from undifferentiated hematopoietic stem cells and thus pro- 
vides an assessment of thymic function in vivo. Previous studies 
have shown that myeloablative regimens markedly reduce thymic 
output of new T cells for 6-9 months following allogeneic trans- 
plant. Moreover, reduced levels of TREC correlate with decreased 
8B&MT 103 
